Lonza invests in new production line in China

Lonza (LONN.S) is investing in new drug product manufacturing capacity at its site in Guangzhou, China, the Swiss company said on Monday.

The sterile, multi-product fill and finish line is expected to be completed in 2022 and will create more than 150 jobs. Lonza, which has been making ingredients for Moderna’s (MRNA.O) COVID-19 vaccine, did not say how much it was spending on the Guangzhou plant.